Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
Authors' conclusion
Extending treatment intervals with canakinumab in colchicine-resistant familial Mediterranean fever shows promise for favorable outcomes.
Study context
- Population
- Children with colchicine-resistant FMF whose canakinumab dose interval was adjusted according to a standard protocol
- Participants
- 45 children
- Outcome
- Outcome of canakinumab dose interval extension
Methodological detailssingle-group, standard protocol determined by Delphi method, Canakinumab initiated once a month for all patients
- Single-group
- Standard protocol determined by Delphi method
- Canakinumab initiated once a month for all patients
Main finding
As reported in the abstract
Attack during first interval extension (6th month); no further extension
7 patients
15.5%
Dose interval successfully extended to once every 3 months (attack-free for a year after first extension)
29 patients
Continued every 2 months (not yet one year since first extension)
9 patients
Observational data: associations, not effects.
Further findings
Association of attack during extension protocol with number and duration of attacks or autoinflammatory diseases activity index score
- No significant correlation
Original publication
Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience. Pediatr Rheumatol Online J. Published 23 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →